Clinical Trials Logo
  1. Home
  2. Treatment Efficacy
  3. NCT05087381

Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community

Treatment Efficacy Clinical Trial

Official title:
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community With Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide in Decreasing Recovery Time

Clinical Trial Summary

There is an urgent need to identify effective treatments for SARS-CoV-2 infection that helps people recover quicker and reduces the need for hospital admission. The investigators develop an open, adaptive, platform trial to evaluate treatments, Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide suitable for use in the community for treating COVID-like-illness that might help people recover sooner and prevent hospitalisation.

Clinical Trial Description

There is an urgent need to identify interventions against COVID-19 suitable for wide use in the community that have been proven to be effective in reducing symptom duration or hospitalisation. There is urgent need to know whether potential COVID-19 treatments such as Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide that are available for rapid pragmatic evaluation might modify the course of COVID-19 infections, particularly among those who are at higher risk of complications, such as those aged 50 years and over with comorbidity and those aged 65 years and over. Most reported trials have been conducted in hospital settings, and there is little evidence from community settings, where most people with COVID-19 receive care and where deployment of effective early treatment could speed time to recovery and reduce complications. The investigators established a multi-arm, adaptive platform, randomised controlled trial for community treatment of COVID-19 syndromic illness in people at higher risk of an adverse illness course. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05087381
Study type Interventional
Source Chulalongkorn University
Contact
Status Completed
Phase Phase 4
Start date October 1, 2021
Completion date June 21, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04508803 - Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer Phase 2
Active, not recruiting NCT02551523 - Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection Phase 2
Recruiting NCT06221722 - Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
Terminated NCT03503968 - TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms Phase 1/Phase 2
Not yet recruiting NCT06460883 - Effects of Eccentric Banded Leg Curls Versus Eccentric Cable Leg Curls Exercises in Cricket Players N/A
Completed NCT02572947 - A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients Phase 2
Completed NCT05144295 - Lubiprostone for Functional Constipation in the Under 18 Years Patients Phase 3
Recruiting NCT05813951 - Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock N/A
Completed NCT03345160 - Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study Phase 2